Background-5ЈAMP-activated protein kinase (AMPK), a well-known regulator of cellular energy status, is also implicated in ischemic preconditioning leading to cardioprotection. We hypothesized that AMPK is involved in anesthetic-induced cardioprotection and that this activation is mediated by reactive oxygen species (ROS). Methods and Results-Isolated Langendorff-perfused rat hearts were subjected to 35 minutes of global ischemia (I) followed by 120 minutes of reperfusion (I/R). Hearts were assigned to a control group (Con) or a sevoflurane (Sevo) group receiving 3 times 5-minute episodes of sevoflurane (2.5vol%) before I/R. Phosphorylation of both AMPK and endothelial nitric oxide synthase (eNOS) were determined by Western blot analysis. Cardioprotection was assessed after I/R from recovery of left ventricular pressure and from infarct size (triphenyltetrazolium chloride staining). In the control group, ischemia resulted in a 2-fold increase in phosphorylation levels of AMPK (Con 0.13Ϯ0.01 versus Con-I 0.28Ϯ0.05, PϽ0.05), which was sustained after 120 minutes of reperfusion (Con-I/R 0.26Ϯ0.02, PϽ0.05). Sevoflurane preconditioning had no affect on AMPK phosphorylation before ischemia (Sevo 0.12Ϯ0.03, PϾ0.05), but almost doubled the increase in AMPK phosphorylation relative to control after ischemia (Sevo-I 0.48Ϯ0.09, PϽ0.05), an effect that was sustained after reperfusion (Sevo-I/R 0.49Ϯ0.12, PϽ0.05). The AMPK-inhibitor compound C (10 mol/L) reduced the sevoflurane-mediated increase in phosphorylation of AMPK and its target eNOS and abolished cardioprotection. The ROS-scavenger n-(2-mercaptopropionyl)-glycine (1 mmol/L) blunted the sevoflurane-mediated increase in AMPK and eNOS phosphorylation and prevented cardioprotection. Conclusions-Sevoflurane-induced AMPK activation protects the heart against ischemia and reperfusion injury and relies on upstream production of ROS. (Circulation. 2009;120[suppl 1]:S10-S15.)
T he heart possesses intrinsic protective mechanisms against ischemia and reperfusion (I/R) injury, which are induced by brief ischemic episodes and rely on protein kinase C (PKC), glycogen synthase kinase 3␤ (GSK3␤), and on production of reactive oxygen species (ROS). 1 Volatile anesthetics, such as sevoflurane, exert cardioprotective properties as well and operate via similar signaling cascades. [2] [3] [4] For instance, sevoflurane-induced production of ROS during the preconditioning period is involved in cardioprotection, 3 whereas sevoflurane preconditioning also reduces the excessive production of ROS after I/R. 5 The in vivo relevance of these processes is demonstrated by De Hert et al, who showed that sevoflurane improved cardiac function in patients during coronary artery bypass surgery 6 and in high-risk patients with reduced cardiac function. 7 5ЈAMP-activated protein kinase (AMPK), an important sensor and regulator of cellular energy status, is activated in response to ischemic stress and is implicated in ischemic preconditioning. 8 In nonischemic hearts, AMPK is activated by hydrogen peroxide (H 2 O 2 ) 9 and peroxynitrite (ONOO Ϫ ). 10 Currently, it is unknown whether AMPK plays a role in volatile anesthetics-induced cardioprotection.
Accordingly, we hypothesize that AMPK activation is involved in anesthetic-induced cardioprotective signaling and that this activation requires production of ROS. Elucidation of the involvement of AMPK in anesthetic-induced cardioprotective signaling may have important implications for the development of clinical cardioprotective strategies, in particular during diabetes mellitus, where intrinsic AMPKdependent signaling is depressed. 8 To test our hypothesis we determined, in isolated Langendorff-perfused rat hearts, the effect of sevoflurane on phosphorylation of AMPK before ischemia, after ischemia, and after reperfusion, as well as myocardial recovery and infarct size after reperfusion. The functional contribution of AMPK was assessed with a specific AMPK-inhibitor, and a ROS-scavenger was used to assess the involvement of ROS.
Methods
An expanded version of Methods is provided in the Online Data Supplement.
Animals and Experimental Set-Up
This study was performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the VU University Medical Center (VUMC), which conforms to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996). Male Wistar rats (nϭ116, 250 to 400g; Harlan, The Netherlands) were anesthetized with pentobarbital (80 mg/kg, intraperitoneal). Subsequently, the heart was rapidly excised and mounted in a Langendorff set-up. Left ventricular (LV) pressures were measured with a balloon inserted in the LV to determine functional recovery.
Experimental Protocol and Assays
To determine whether sevoflurane induces AMPK phosphorylation, hearts were assigned to 2 groups: (1) Control (Con) group: no preconditioning; (2) Sevoflurane (Sevo) group: preconditioning by application of 3 times 5-minute episodes of sevoflurane (2.5vol%) separated by 5 minutes of washout. Hearts from both groups were frozen in liquid nitrogen immediately before ischemia, immediately after 35 minutes of global ischemia (I), or after 35 minutes of global ischemia followed by 120 minutes of reperfusion (I/R).
The contribution of sevoflurane-induced activation of AMPK and the involvement of ROS to the improved myocardial recovery and reduced infarct size were investigated by subsequently assigning hearts of the control and sevoflurane group to subgroups identified by the following inhibitors: (1) reversible AMPK inhibitor compound C (CC, 10 and 1 mol/L), (2) ROS-scavenger n-(2-mercaptopropionyl)-glycine (MPG, 1 mmol/L), (3) both MPG (1 mmol/L) and CC (10 mol/L), and (4) NOS-inhibitor N-nitro-L-arginine (L-NA, 0.1 mmol/L).
Recovery of LV pressures was determined, and infarct size was assessed from triphenyltetrazolium chloride (TTC)-stained sections. Western blot analysis of LV apex samples was used for determination of AMPK phosphorylation with an antibody against phospho-AMPK␣ at Thr 172 . AMPK activity was determined by measuring eNOS phosphorylation with an antibody against phospho-eNOS at Ser 1177 .
Statistical Analysis
Levels of AMPK phosphorylation between the control and sevoflurane group at 3 different time points (before ischemia, after ischemia, after I/R) were obtained in different hearts and therefore analyzed using 2-way ANOVA. Differences in AMPK and eNOS phosphorylation, recovery of cardiac function (P developed , P diastolic , and ϩdP/dt) and infarct size between the control and sevoflurane groups with and without CC were also analyzed with 2-way ANOVA, whereas the effects of MPG and the combination of MPGϩCC were analyzed with multiple ANOVA. The interaction term indicated whether the effect of the inhibitor was different between the control and sevoflurane group. A Bonferroni post hoc test was used to assess the effect of the inhibitor within the control and sevoflurane group. A value of PϽ0.05 was considered significant. All data are expressed as meansϮSEM.
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Results

Sevoflurane Enhances the Ischemia-Induced Increase in AMPK-Phosphorylation
In Figure 1A are shown representative examples and averaged values of the phosphorylation levels of AMPK␣ at Thr 172 in LV cardiac tissue of the control and sevoflurane group, before ischemia, after ischemia, and after ischemia and reperfusion. In the control group, 35 minutes of ischemia resulted in an almost 2-fold increase in AMPK phosphorylation, an effect that was sustained after reperfusion. Before ischemia, sevoflurane preconditioning had no effect on phosphorylation levels of AMPK. However, after ischemia, sevoflurane preconditioning resulted in an almost 4-fold increase in AMPK-phosphorylation relative to the control group before ischemia, which was sustained after reperfusion. This implies a 2-fold increase of AMPK phosphorylation by sevoflurane preconditioning during ischemia. Figure 1B shows that the sevoflurane-induced increase in AMPK phosphorylation after I/R was blocked by addition of 10 mol/L of the AMPK-inhibitor compound C (CC), whereas in the Con I/R group, the levels of phosphorylation of AMPK remained unaffected, although a trend to increased levels existed. Addition of a lower dose (1 mol/L) of CC had a similar effect (data not shown). The phosphorylation of eNOS, a well-known target of AMPK and an index of its activity, was increased in the Sevo I/R group compared to control I/R group. The AMPK-inhibitor CC (10 mol/L) abolished the sevoflurane-induced increase in eNOS phosphorylation after I/R. This indicates that AMPK-phosphorylation and its activity were blocked. In addition, the NOS inhibitor L-NA (0.1 mmol/L) also abolished the sevoflurane-induced increase in eNOS phosphorylation after I/R (Con I/R L-NA: 0.22Ϯ0.04% versus Sevo I/R L-NA: 0.28Ϯ0.05%, nϭ5).
AMPK Inhibition Blocks Sevoflurane-Induced Increase in AMPK Phosphorylation and Activity
Sevoflurane-Induced AMPK Activation Contributes to Cardioprotection
Anesthetic preconditioning with sevoflurane was evident after I/R from an increased recovery of P developed and ϩdP/dt max compared to controls (Figure 2A, nϭ8) . P diastolic values were not different between groups after I/R. This sevofluraneinduced improved functional cardiac recovery was abolished by addition of 10 mol/L of the AMPK inhibitor CC (Figure  2A, nϭ8) . A lower concentration of CC (1 mol/L) also blocked the sevoflurane-induced improved functional recovery of P developed (Con I/R CC: 43Ϯ3% versus Sevo I/R CC: 47Ϯ5%, nϭ5). In addition, the NOS inhibitor L-NA also blocked the sevoflurane-induced improved functional recovery (Con I/R L-NA: 37.4Ϯ4% versus Sevo I/R L-NA: 43.1Ϯ5%, nϭ5). In time control experiments, without I/R, the LV P developed at the end of the experiment (200 minutes) amounted to approximately Ϸ80% of the value before ischemia (Figure 2A) . Contribution of sevoflurane-induced AMPK activation to cardioprotection A, Examples of left ventricular pressure (LVP) tracing during a contraction and averaged data of LV P diastolic , recovery of P developed and recovery of ϩdP/dt max in isolated rat hearts in the control (Con) and sevoflurane (Sevo) group after ischemia and reperfusion (I/R) in the presence of AMPK-inhibitor compound C (CC, 10 mol/L) and in time control groups. B, Examples and averaged data of infarct size determined with TTC staining in isolated rat hearts in control and sevoflurane groups after I/R in the presence of CC. Two-way ANOVA revealed that preconditioning with 2.5vol% sevoflurane resulted in a significant increased recovery of P developed and a reduced infarct size compared to controls. The interaction in the 2-way ANOVA revealed that this effect was abolished by CC. Values are expressed as meansϮSEM, nϭ8 per group, #PϽ0.05 Sevo vs Control, *PϽ0.05 CC vs no-CC (post hoc).
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The analysis of the TTC-stained heart slices shown in Figure 2B revealed that sevoflurane preconditioning substantially reduced infarct size after I/R compared to controls (nϭ8). The sevoflurane-induced reduction in infarct size was blocked by AMPK inhibitor CC at the high (10 mol/L; Figure 2B , nϭ8), as well as the lower (1 mol/L) concentration (Infarct size: Con I/R CC: 23Ϯ4% versus Sevo I/R CC: 22Ϯ3%, nϭ5). In control hearts CC decreased infarct size ( Figure 2B ). In addition, the NOS inhibitor L-NA (0.1 mmol/L) also blocked the sevoflurane-induced reduction in infarct size (Con I/R L-NA 28Ϯ4% versus Sevo I/R L-NA 26Ϯ4%, nϭ5).
In the time control group, without I/R, myocardial damage was only 1.6Ϯ0.8% (nϭ8). In additional experiments (nϭ3), we found that DMSO, used as vehicle for dissolving CC, did not affect the functional recovery after I/R (P developed : 44Ϯ6%), nor did it reduce infarct size (30Ϯ4%).
Sevoflurane-Induced AMPK Activation Relies on Production of ROS
Scavenging of ROS by addition of 1 mmol/L MPG during sevoflurane preconditioning (nϭ5) reduced the phosphorylation levels of AMPK ( Figure 3A ) and eNOS ( Figure 3B ) after I/R. This was accompanied by blunting of functional recovery ( Figure 3C ) and an increased infarct size ( Figure 3D ). In the control group, without sevoflurane, no effects of MPG on AMPK or eNOS phosphorylation, functional cardiac recovery, and infarct size were observed (nϭ5). In addition, the combination of ROS scavenging (MPG) with AMPK inhibition (CC) resulted in phosphorylation levels of AMPK and eNOS ( Figure 3A and 3B) that were not different between control and sevoflurane groups (both nϭ5) and that were equivalent to the levels found with either inhibitor alone. Similar results were found for functional recovery ( Figure  3C ) and the infarct size ( Figure 3D ).
Discussion
The main finding of this study is that sevoflurane pretreatment enhances AMPK activation during ischemia. This activation results in improved myocardial recovery and reduced infarct size, as became apparent from the experiments in which the AMPK-inhibitor compound C was used. In addition, ROS scavenging during sevoflurane preconditioning blunted AMPK activation and abolished cardioprotection. This indicates that sevoflurane-induced cardioprotection is mediated via ROS-dependent activation of AMPK. Our study demonstrates for the first time a direct link between AMPK activation and the production of ROS in anesthetic-induced cardioprotection.
The present study clearly shows that sevoflurane preconditioning enhances the increase in AMPK phosphorylation after ischemia, as well as after reperfusion. Although sevoflurane did not immediately activate AMPK ( Figure 1A) , it apparently primed the myocardium and doubled the increase in AMPK phosphorylation observed after ischemia, which persisted after reperfusion. This suggests that the ischemic conditions are necessary to activate AMPK. Phosphorylation of eNOS ( Figure 1B) , a well-known target of AMPK in cardioprotective signaling, 11 was increased as well, indicating that changes in AMPK phosphorylation reflect changes in AMPK activity. The sevoflurane-induced increase in AMPK and eNOS phosphorylation was blunted by the AMPK-inhibitor compound C. Compound C, as well as NOS inhibitor L-NA, abolished the effects of sevoflurane on myocardial recovery and infarct size, indicating that the sevoflurane-induced increased in phosphorylation of AMPK and eNOS during ischemia are functionally related to the cardioprotection. In our control hearts compound C decreased infarct size, which was accompanied by a trend to increased levels of AMPK phosphorylation. Khaliulin et al 12 noted in isolated rat hearts that compound C enhanced cardioprotection induced by temperature preconditioning and suggested that this paradoxical effect of compound C might be related to altering the balance between the beneficial and detrimental AMPK activation during I/R. 13 The ischemia-induced AMPK activation has the potential to increase myocardial energy supply by glycolysis during ischemia and by glucose uptake during reperfusion, thereby exerting a cardioprotective effect. However, AMPK activation can also stimulate fatty acid oxidation, which can increase proton production and decrease cardiac efficiency by concomitant inhibition of glucose oxidation. 13 These dual effects of AMPK on metabolic pathways, ion channels, protein synthesis, and cellular function reflect its complex role during I/R. Our results show that inhibition of ROS with MPG completely abolished the sevoflurane-induced AMPK phosphorylation as well as cardioprotection. Hence, our results indicate that the additional activation of AMPK by sevoflurane during ischemia is beneficial as it protects against I/R injury. The absence of an effect of MPG on AMPK phosphorylation and infarct size in control hearts illustrates the complex role of AMPK during I/R-injury.
How does sevoflurane enhance AMPK activation during ischemia? During severe ischemia, intracellular ATP levels drop, resulting in a substantial rise of the intracellular concentration of 5Ј-AMP in the heart, which will lead to AMPK activation. 14 Sevoflurane does not influence intracellular 5Ј-AMP levels in the heart, and no effects of sevoflurane were found on intracellular myocardial ATP levels. 15 Thus, alternative mechanisms of AMPK activation should be considered.
The present study shows that the ROS-scavenger MPG blunted the sevoflurane-induced enhanced AMPK activation after I/R and that this was accompanied by an inhibition of cardioprotection. MPG was applied during the preconditioning period, thus before the ischemic period when AMPK activation took place. This indicates that sevoflurane-induced AMPK activation is ROS-dependent. In addition, combining ROS scavenging with AMPK inhibition did not result in an additional effect on AMPK activation or cardioprotection, indicating that the production of ROS is upstream of AMPK activation in the same signaling pathway. MPG scavenges hydroxyl radicals and ONOO Ϫ but not H 2 O 2 and superoxide. 16 Moreover, ONOO Ϫ reduced myocardial infarct size in cats after I/R. 17 These data, in combination with previous observations from our laboratory showing that MPG is able to inhibit the sevoflurane-induced ONOO Ϫ modification of tyrosine residues, 3 indicate that ONOO Ϫ is the most likely mediator for sevoflurane-induced ROS-dependent activation of AMPK. The excessive ROS production during reperfusion is detrimental for the heart, 18 whereas small amounts of ROS generated during preconditioning prove to be beneficial, 5 as also indicated by the present study.
Several other upstream factors, such as the tumor suppressor protein LKB1, the calcium/calmodulin-dependent kinase kinase (CaMKK)-␤, 19 or the kinase H11K, 20 are able to activate AMPK. Cardiac AMPK activation was also linked to activation of PKC and inhibition of GSK3␤. 20, 21 Volatile anesthetics, such as sevoflurane, isoflurane, and desflurane, also influence these kinases. [2] [3] [4] [22] [23] [24] For instance, activation of different isoforms of PKC, which was preceded by ROS production, and extracellular signal-regulated kinase 1/2 (ERK1/2) have been demonstrated in volatile anesthetic-induced cardioprotective signaling. 3, 22, 23 In addition, isoflurane pre-and postconditioning was linked to activation of phosphatidylinositol 3-kinase inhibitor (PI3K) 24 and GSK3␤. 4 Our experiments clearly indicate that sevoflurane-preconditioning alters ROS production, but future experiments will be needed to elucidate how these kinases relate to AMPK-dependent cardioprotective signaling.
The isolated Langendorff perfused heart preparation in present study was chosen to examine the underlying cardiac mechanism of sevoflurane cardioprotection under controlled ex vivo conditions to exclude possible confounding systemic hemodynamics and humoral effects of sevoflurane and the inhibitors. Caution should be exerted when extrapolating these findings to the in vivo situation, although the intracellular mechanism revealed most likely is important for anesthetic preconditioning in patients.
Conclusion
Sevoflurane-induced AMPK activation protects the heart against ischemia and reperfusion injury and relies on upstream production of ROS. Therefore, the present study indicates that AMPK is not only a key regulator of energy status, but also plays a pivotal role in anesthetic cardioprotection.
